Roche’s Genentech Loses Bid to Block Amgen’s Mvasi During Appeal

The U.S. Court of Appeals for the Federal Circuit denied Genentech’s request to halt sales of Amgen’s Mvasi biosimilar while it appeals a trial court ruling that let the sales proceed.

The Federal Circuit on Aug. 7 had denied a similar request involving Amgen’s Kanjinti.

Mvasi is a biosimilar of Genentech’s colorectal cancer drug Avastin; Kanjinti is biosimilar of its Herceptin.

Amgen has conceded infringing Genentech patents; the issue before the trial court is their validity.

Genentech had argued the biosimilars should be kept off the market until the validity issues are resolved; Amgen said Genentech waited too long to ...